208 Life Science patents (classification A61K) were issued by the US Patent and Trademark Office on Tuesday 27 September 2016 (click here). Two went to Australian assignees.
US Patent 9,452,307 was granted to the Perth-based drug delivery company OBJ Ltd (ASX: OBJ) for Delivery of oral care products. This patent covers methods to deliver oral care products via magnetic disruption of the tissue barrier.
US Patent 9,452,148 was granted to Verva Pharmaceuticals, the spin-out from Chemgenex, for Insulin sensitisers and methods of treatment. This patent covers carbonic anhydrase inhibitors for the treatment of insulin resistance.
Over the last twelve months the Australian Life Science sector has been granted 123 US patents, versus 127 in the previous corresponding period.
To look at US Life Science patent issuance since the beginning of 2014 to Australian assignees, click here. For US Life Science patent issuance to New Zealand assignees click here.